Financial Statements of

# UNIVERSITY HOSPITAL FOUNDATION



KPMG LLP 2200, 10175 – 101 Street Edmonton, AB T5J 0H3 Telephone (780) 429-7300 Fax (780) 429-7379 www.kpmg.ca

#### INDEPENDENT AUDITORS' REPORT

To the Trustees of University Hospital Foundation

#### **Opinion**

We have audited the financial statements of University Hospital Foundation (the Entity), which comprise:

- the statement of financial position as at March 31, 2020
- the statement of operations and changes in fund balances for the year then ended
- the statement of cash flows for the year then ended
- and notes to the financial statements, including a summary of significant accounting policies (Hereinafter referred to as the "financial statements").

In our opinion, the accompanying financial statements, present fairly, in all material respects, the financial position of the Entity as at March 31, 2020, and its results of operations and its cash flows for the year then ended in accordance with Canadian Accounting standards for not-for-profit organizations.

#### Basis for Opinion

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the "Auditors' Responsibilities for the Audit of the Financial Statements" section of our auditors' report.

We are independent of the Entity in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

# Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with Canadian accounting standards for not-for-profit organizations, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.



In preparing the financial statements, management is responsible for assessing the Entity's ability to continue as a going concern, disclosing as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Entity or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Entity's financial reporting process.

### Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists.

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit.

#### We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud
  or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that
  is sufficient and appropriate to provide a basis for our opinion.
  - The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that
  are appropriate in the circumstances, but not for the purpose of expressing an opinion on the
  effectiveness of the Entity's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Entity to cease to continue as a going concern.



- Evaluate the overall presentation, structure and content of the financial statements, including the
  disclosures, and whether the financial statements represent the underlying transactions and events in a
  manner that achieves fair presentation.
- Communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

**Chartered Professional Accountants** 

KPMG LLP

Edmonton, Canada June 24, 2020

### Financial Statements

ı	F	in	าว	ncia	a١	S	tat	ŀΔ	m	Δr	nte
ı	г	ш	М	11071	11	o	ıaı	ı	111	ЮI	115

Statement of Financial Position	1
Statement of Operations and Changes in Fund Balances	2
Statement of Cash Flows	3
Notes to Financial Statements	4-11
Schedules	
Schedule 1 - Fund Balances	12-23
Schedule 2 - Investment Income	24

Statement of Financial Position

As at March 31, 2020, with comparative information for 2019

	2020	201
Assets		
Current assets:		
Cash and cash equivalents	\$ 20,732,024	\$ 18,506,37
Restricted cash (note 3)	658,189	1,587,019
Accounts receivable	249,465	2,575,772
Accrued interest receivable	568,376	605,554
Prepaid expenses and deposits Other assets	89,958	138,48
Other assets	2,208,417	1,186,848
	24,506,429	24,600,047
Investments (note 4)	148,702,457	152,424,91
Equipment (note 5)	40,370	132,52
	\$ 173,249,256	\$ 177,157,483
Liabilities and Fund Balances		
Current liabilities: Accounts payable and accrued liabilities (note 6)	\$ 3,108,301	\$ 5,726,422
Current liabilities:	\$ 3,231,215	\$ 3,613,493
Current liabilities: Accounts payable and accrued liabilities (note 6)	\$	\$
Current liabilities: Accounts payable and accrued liabilities (note 6)	\$ 3,231,215	\$ 3,613,493
Current liabilities: Accounts payable and accrued liabilities (note 6) Deferred revenue	\$ 3,231,215 6,339,516	\$ 3,613,493 9,339,918
Current liabilities:     Accounts payable and accrued liabilities (note 6)     Deferred revenue  Distributions payable (note 6)  Fund balances (Schedule 1):     Endowment funds	\$ 3,231,215 6,339,516	\$ 3,613,493 9,339,918
Current liabilities:     Accounts payable and accrued liabilities (note 6)     Deferred revenue  Distributions payable (note 6)  Fund balances (Schedule 1):     Endowment funds     Externally restricted funds	\$ 3,231,215 6,339,516 2,153,394	\$ 3,613,493 9,339,915 2,153,394
Current liabilities:     Accounts payable and accrued liabilities (note 6)     Deferred revenue  Distributions payable (note 6)  Fund balances (Schedule 1):     Endowment funds     Externally restricted funds     Internally restricted funds	\$ 3,231,215 6,339,516 2,153,394 6,751,652 117,765,085 21,297,244	\$ 3,613,493 9,339,915 2,153,394 9,323,400 108,683,490 20,147,083
Current liabilities:     Accounts payable and accrued liabilities (note 6)     Deferred revenue  Distributions payable (note 6)  Fund balances (Schedule 1):     Endowment funds     Externally restricted funds     Internally restricted funds     Invested in capital assets	\$ 3,231,215 6,339,516 2,153,394 6,751,652 117,765,085 21,297,244 40,370	\$ 3,613,493 9,339,915 2,153,394 9,323,400 108,683,490 20,147,083 132,525
Current liabilities:     Accounts payable and accrued liabilities (note 6)     Deferred revenue  Distributions payable (note 6)  Fund balances (Schedule 1):     Endowment funds     Externally restricted funds     Internally restricted funds	\$ 3,231,215 6,339,516 2,153,394 6,751,652 117,765,085 21,297,244 40,370 18,901,995	\$ 3,613,493 9,339,915 2,153,394 9,323,400 108,683,490 20,147,082 132,525 27,377,678
Current liabilities:     Accounts payable and accrued liabilities (note 6)     Deferred revenue  Distributions payable (note 6)  Fund balances (Schedule 1):     Endowment funds     Externally restricted funds     Internally restricted funds     Invested in capital assets     Unrestricted funds	\$ 3,231,215 6,339,516 2,153,394 6,751,652 117,765,085 21,297,244 40,370	\$ 3,613,493 9,339,915 2,153,394 9,323,400 108,683,490 20,147,083 132,525
Current liabilities:     Accounts payable and accrued liabilities (note 6)     Deferred revenue  Distributions payable (note 6)  Fund balances (Schedule 1):     Endowment funds     Externally restricted funds     Internally restricted funds     Invested in capital assets	\$ 3,231,215 6,339,516 2,153,394 6,751,652 117,765,085 21,297,244 40,370 18,901,995	\$ 3,613,493 9,339,915 2,153,394 9,323,400 108,683,490 20,147,082 132,525 27,377,678

On behalf of the Board:

David Finlay

Chair, Board of Trustees

Don Wheaton

Chair, Finance & Investment Committee

Statement of Operations and Changes in Fund Balances

Year ended March 31, 2020, with comparative information for 2019

	Endowment Funds	Externally Restricted Funds	Internally Restricted Funds	Invested in Capital Assets	Unrestricted Funds	Total 2020	Total 2019
Revenue:							
Fundraising	\$ 622,634	\$ 18,134,844	\$ -	\$ -	\$ 1,970,561	\$ 20,728,039	\$ 29,473,137
Lotteries (note 3)		7,198,960	<u>-</u>	-		7,198,960	7,189,999
Realized investment income (Schedules 1 and 2)	3,306	1,563,762	230,128	-	11,353,410	13,150,606	7,885,484
Special events	-	-	-	-	2,050,720	2,050,720	2,697,209
	625,940	26,897,566	230,128	=	15,374,691	43,128,325	47,245,829
Expenditures:							
Lotteries (note 3)	-	5,169,886	-	_	-	5,169,886	4,959,897
Fundraising	-	491,990	-	=	3,928,601	4,420,591	3,812,159
Administrative	-	5,130	-	=	3,068,075	3,073,205	2,390,874
Special events	-	-	-	-	1,750,352	1,750,352	1,545,827
Investment costs	-	-	-	-	436,660	436,660	506,876
Amortization of equipment	-	-	-	92,155	-	92,155	96,225
	-	5,667,006	-	92,155	9,183,688	14,942,849	13,311,858
Excess (deficiency) of revenue over expenditures before other items	625,940	21,230,560	230,128	(92,155)	6,191,003	28,185,476	33,933,971
Unrealized gain (loss) on investments (Schedule 2)						(12 662 406)	1,546,851
Officialized gain (loss) on investments (Schedule 2)	-	-	-	-	(13,662,406)	(13,662,406)	1,540,651
Distributions to charitable organizations (note 6 and Schedule 1)	(3,197,688)	(11,528,930)	-	-	(704,280)	(15,430,898)	(13,111,033)
Excess (deficiency) of revenue over expenditures	(2,571,748)	9,701,630	230,128	(92,155)	(8,175,683)	(907,828)	22,369,789
Fund balances, beginning of year	9,323,400	108,683,490	20,147,081	132,525	27,377,678	165,664,174	143,294,385
Transfers	-	(620,035)	920,035	-	(300,000)	-	-
Fund balances, end of year	\$ 6,751,652	\$ 117,765,085	\$ 21,297,244	\$ 40,370	\$ 18,901,995	\$ 164,756,346	\$ 165,664,174

See accompanying notes to financial statements.

Statement of Cash Flows

Year ended March 31, 2020, with comparative information for 2019

		2020		2019
Cash provided by (used in):				
Operations:				
Excess (deficiency) of revenue over expenditures Items not involving cash:	\$	(907,828)	\$	22,369,789
Amortization of equipment		92,155		96,225
Realized gains on investments		(7,559,289)		(2,355,003)
Unrealized loss (gain) on investments Change in non-cash operating working capital:		13,662,406		(1,546,851)
Decrease (increase) in accounts receivable		2,326,307		(2,415,795)
Decrease (increase) in accrued interest receivable Decrease (increase) in prepaid expenses		37,178		(149,850)
and deposits		48,523		(19,520)
Decrease (increase) in other assets Decrease in accounts payable		(1,021,569)		59,650
and accrued liabilities		(2,618,121)		(305,570)
Decrease in distributions payable		-		(2,926,535)
Decrease (increase) in deferred revenue		(382,278)		289,621
		3,677,484		13,096,161
Investments:				
Net purchases of investments		(2,380,663)		(10,441,999)
Purchase of equipment		-		(10,531)
		(2,380,663)		(10,452,530)
Increase in cash position		1,296,821		2,643,631
Cash position, beginning of year		20,093,392		17,449,761
Cash position, end of year	\$	21,390,213	\$	20,093,392
Cash position consists of:	•	47 700 440	Φ.	40,000,057
Cash	\$	17,708,143	\$	13,008,257
Cash equivalents		3,023,881		5,498,116
Restricted cash		658,189		1,587,019
	\$	21,390,213	\$	20,093,392

See accompanying notes to financial statements.

Notes to Financial Statements

Year ended March 31, 2020, with comparative information for 2019

#### 1. Authority:

University Hospital Foundation (the "Foundation") operates under the Regional Health Authorities Foundations Regulation. The Foundation is a registered public charity under the Income Tax Act (Canada) and accordingly, is exempt from income taxes, provided certain requirements of the Income Tax Act are met.

The purpose of the Foundation is to seek and receive by gift, bequest, transfer or other, property of every nature and description and, subject to any prior trust conditions or other conditions imposed on the use of that property, to hold, use and administer the property to support innovation and excellence at the University of Alberta Hospital (the "Hospital"), the Mazankowski Alberta Heart Institute ("Heart Institute") and the Kaye Edmonton Clinic (the "Clinic") and affiliated programs as a center of excellence for patient care, education and research for the greater benefit of the people of Alberta and Canada.

#### 2. Significant accounting policies:

These financial statements have been prepared by management in accordance with Canadian accounting standards for not-for-profit organizations in Part III of the CPA Canada Handbook. The Foundation's significant accounting policies are as follows:

#### (a) Fund accounting:

These financial statements include the following funds:

<u>Endowment funds</u> - consist of donations for which the principal is permanently restricted and undistributed investment income capitalized to principal as per the terms of reference.

<u>Externally restricted funds</u> - consist of funds, including principal and investment income, and the Foundation's share of excess of revenues over expenditures of the Full House Lottery, upon which restrictions have been imposed by the donor or external parties.

<u>Internally restricted funds</u> - consist of funds upon which restrictions have been imposed by the Board of Trustees ("Board"). These funds represent donations and income that was initially unrestricted which the Board has restricted for a specific priority program at the Hospital, Heart Institute, or Clinic.

<u>Unrestricted funds</u> - consist of donations and investment income upon which no restrictions have been imposed by the donor or the Board. These funds are managed in accordance with general Board policies, and may be restricted through Board motion.

Notes to Financial Statements (continued)

Year ended March 31, 2020, with comparative information for 2019

#### 2. Significant accounting policies (continued):

#### (b) Full House Lottery:

The Foundation accounts for its interests in the Full House Lottery using the proportionate consolidation method.

#### (c) Cash and cash equivalents:

The Foundation considers deposits in banks, certificates of deposit and short-term investments with original maturities of three months or less as cash and cash equivalents. Restricted cash is subject to external restrictions related to the Full House Lottery.

#### (d) Financial instruments and risk management:

Financial instruments are recorded at fair value on initial recognition. Freestanding derivative instruments that are not in a qualifying hedging relationship and equity instruments that are quoted in an active market are subsequently measured at fair value. All other financial instruments are subsequently recorded at cost or amortized cost, unless management has elected to carry the instruments at fair value. The Foundation has elected to carry its investments at fair value.

Transaction costs incurred on the acquisition of financial instruments measured subsequently at fair value are expensed as incurred. All other financial instruments are adjusted by transaction costs incurred on acquisition and financing costs, which are amortized using the straight-line method.

Financial assets that are carried at cost or amortized cost are assessed for impairment on an annual basis. If there are indicators of impairment, the carrying value of financial assets is reduced to reflect the higher of the future expected cash flows and the net realizable value. Should the impairment reverse in a subsequent period, the carrying value of the financial assets will be increased to the extent of the reversal, not exceeding the initial carrying value.

#### (e) Equipment:

Equipment is recorded at cost less accumulated amortization. Amortization is provided on a straight-line basis at the rate of 20% per annum.

Notes to Financial Statements (continued)

Year ended March 31, 2020, with comparative information for 2019

#### 2. Significant accounting policies (continued):

#### (f) Revenue recognition:

Under the restricted fund basis of accounting for contributions, revenue is recognized as follows:

- (i) Contributions for general operations and unrestricted contributions are recognized as revenue of the unrestricted funds in the year received or receivable if the amount to be received can be reasonably estimated and collection is reasonably assured. All restricted contributions are recognized as revenue of the externally restricted funds in the year.
- (ii) Contributions for endowment are recognized as revenue in the Endowment Funds.
- (iii) Investment income earned on endowment funds that must be used in accordance with the conditions imposed by the donor is recognized as revenue of the externally restricted funds. Investment income earned on endowment funds that must be added to the endowment principal is recognized as revenue of the endowment fund. Unrestricted investment income earned on endowment funds is recognized as revenue of the unrestricted funds. Other investment income is recognized as revenue of the unrestricted funds when earned.
- (iv) Lottery and special events revenue are recognized as of the date of the lottery prize draw or event as Lottery or event revenues cannot be reasonably estimated until the date of the lottery prize draw or event.

#### (g) Contributed materials and services:

Contributed materials and services are recorded at fair value when they would have otherwise been purchased and when a fair value can be reasonably estimated. Contributed services of volunteers are not recognized in these financial statements as their fair value cannot be reasonably determined.

(h) Allocation of fundraising and general expenses:

The Foundation classifies expenses on the Statement of Operations and Changes in Fund Balances by function and does not allocate expenses between functions.

#### (i) Use of estimates:

The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amount of revenue and expenditures during the period. Actual results could differ from these estimates.

Notes to Financial Statements (continued)

Year ended March 31, 2020, with comparative information for 2019

#### 3. Full House Lottery joint venture:

These financial statements include the Foundation's proportionate share (50%) of the Full House Lottery as follows:

		2020		2019
Assets				
Restricted cash	\$	658,189	\$	1,587,019
Accounts receivable		110,020		87,651
Other assets*		1,733,417		1,186,848
	\$	2,501,626	\$	2,861,518
Liabilities and Net Deficiency				
Accounts payable and accrued liabilities	\$	543,453	\$	406,944
Deferred revenue**		3,231,215		3,613,493
		3,774,668		4,020,437
Net deficiency		(1,273,042)		(1,158,919)
	\$	2,501,626	\$	2,861,518
		2020		2019
Revenue	\$	7,198,960	\$	7,189,999
Expenditures	Ψ	5,169,886	Ψ	4,959,897
Partner allocation		2,143,197		2,134,569
Excess (deficiency) of revenue over				
expenditures and distributions		(114,123)		95,533
Cash from operating activities		608,653		1,489,467

<sup>\*</sup>Other assets include lottery prizes that will be awarded subsequent to the draw date of July 9, 2020 (2019 - July 5, 2019).

During the year the Foundation purchased a home from the Full House Lottery with the intention to resell the home on the open market. As at March 31, 2020, the home purchased from the Full House Lottery had not sold. The Foundation's share of the net realizable value of the home of \$475,000 is recorded as Other Assets on the Statement of Financial Position.

<sup>\*\*</sup>Lottery revenues and expenses are deferred until the draw date of July 9, 2020 (2019 - July 5, 2019)

Notes to Financial Statements (continued)

Year ended March 31, 2020, with comparative information for 2019

#### 4. Investments:

	2020	2019
Bonds		
Pooled Bond Funds	\$ 2,010,452	\$ 1,927,618
Government of Canada bonds	20,648,073	18,811,042
Provincial bonds	20,303,965	20,911,459
Municipal bonds	1,931,451	1,905,633
Corporate bonds	28,127,383	28,537,949
Total bonds	73,021,324	72,093,701
Equities		
Canadian common shares	14,109,298	18,453,855
Mutual funds		
Canadian mutual funds	6,186,551	3,758,824
United States mutual funds	27,655,551	28,545,129
International mutual funds	27,572,559	29,427,733
Total mutual funds	61,414,661	61,731,686
Cash surrender value of life insurance policies	157,174	145,669
	\$ 148,702,457	\$ 152,424,911

Face value of the bonds is \$70,351,066 (2019 - \$63,959,389) of which 0% (2019 - 2.79%) mature within the next fiscal year and 34.52% (2019 - 56.07%) mature within the next five years.

The Foundation believes it is not exposed to significant liquidity risk as all investments are held in instruments that are highly liquid and can be disposed of to settle commitments. The fixed income securities yield interest between 1.25% and 10.00% and have maturities ranging from 2021 to 2051.

#### 5. Equipment:

	2020	2019
Equipment Less accumulated amortization	\$ 1,237,979 (1,197,609)	\$ 1,237,979 (1,105,454)
Net book value	\$ 40,370	\$ 132,525

Notes to Financial Statements (continued)

Year ended March 31, 2020, with comparative information for 2019

#### 6. Related party transactions:

The Foundation provides donations of money and gifts in kind to the Hospital, Heart Institute and Clinic. These donations allow the Hospital, Heart Institute and Clinic to provide equipment, patient services, education and research not funded from other sources. The cash donations are included in distributions to charitable organizations.

Accommodation and certain overhead costs incurred in the administration of the Foundation, borne by the Hospital, Heart Institute and Clinic, are not recorded in these financial statements as the value of the services is not readily determinable.

At March 31, 2020, accounts payable and accrued liabilities includes \$1,530,209 (2019 - \$380,901) payable to Alberta Health Services ("AHS") for certain salaries and services paid by AHS on the Foundation's behalf as well as distributions to the Hospital, Heart Institute and Clinic in support of research and patient care programs. These transactions are in the normal course of operations and are measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties.

During the year ended March 31, 2020, the Foundation distributed \$15,430,898 (2019 - \$13,111,033) to the Hospital, the Heart Institute and Clinic, the University of Alberta, and other charitable organizations. During the year ending March 31, 2018, the Foundation accrued a large distribution of \$9,433,088 for payment over the next two fiscal years. Of this amount, \$7,279,694 was paid to AHS during the 2018-2019 fiscal year and \$2,153,394 (2019 - \$2,153,394) remains recorded in distributions payable as at March 31, 2020.

# 7. Additional information to comply with the disclosure requirement of the Charitable Fund Raising Act and Regulation:

In fiscal 2020, \$2,675,968 (2019 - \$2,093,416) was paid as remuneration to employees whose principal duties involve fundraising.

Notes to Financial Statements (continued)

Year ended March 31, 2020, with comparative information for 2019

#### 8. Pledge commitments:

The Foundation has received signed pledge agreements in the amount of \$12,854,314 (2019 - \$15,247,855) from donors which have not been recognized as revenue at year-end. Receipt of the amounts pledged is expected by the Foundation as follows:

	2021	2022	2023	Thereafter
Prostate Health Clinic Brain Centre Campaign University of Alberta Hospital	\$ 1,045,000 806,000 278,185	\$ 1,045,000 761,000 149,881	\$ 1,020,000 530,147 204,761	\$ 5,020,000 1,859,500 134,840
Total	\$ 2,129,185	\$ 1,955,881	\$ 1,754,908	\$ 7,014,340

#### 9. Funding commitments:

The Foundation has the following cumulative funding commitments, as approved by the Board, which are expected to be fulfilled within the next three years:

	2020	2019
University of Alberta Hospital Mazankowski Alberta Heart Institute Brain Centre Campaign Prostate Health Clinic	\$ 17,947,146 11,511,742 8,892,375 1,164,947	\$ 21,324,809 2,165,000 7,909,045 1,164,947
	\$ 39,516,210	\$ 32,563,801

#### 10. Financial risks:

Income and financial returns on investments are exposed to credit and price risks. Credit risk relates to the possibility that a loss may occur from the failure of another party to perform according to the terms of the contract. Price risk is comprised of interest rate, foreign exchange and market risk. Interest rate risk relates to the possibility that the investments will change in value due to future fluctuations in market interest rates. Foreign exchange risk relates to the possibility that the investments will change in value due to fluctuations in foreign currencies. Market risk relates to the possibility that the investments will change in value due to future fluctuations in market prices.

These risks are mitigated by the Foundation's investment policies, which prescribe the investment asset mix including the degree of liquidity and concentration and the amount of foreign content.

Notes to Financial Statements (continued)

Year ended March 31, 2020, with comparative information for 2019

#### 10. Financial risks (continued):

Changes in interest rates and credit ratings are the main cause of changes in the fair value of government securities and corporate bonds resulting in a favorable or unfavorable variance compared to book value. Credit risk is mitigated by investing in securities such that an average credit rating of A or better is achieved and diversifying the securities between government, government backed and corporate issuers. Interest rate risk is mitigated by managing maturity dates and payment frequency. The Foundation limits credit risk associated with other financial assets by dealing with counterparties that it believes are creditworthy.

The Foundation does not use derivative instruments to alter the effects of interest, market and foreign exchange risks.

#### 11. Subsequent event:

Prior to the Foundation's year-end, the COVID-19 outbreak was declared a pandemic by the World Health Organization and has had a significant financial, market and social dislocating impact.

At the time of approval of these financial statements, the Foundation has experienced the following indicators of financial implications and undertaken the following activities in relation to the COVID-19 pandemic:

- Temporary decline and recovery in the fair value of investments and investment income;
- Closure of administrative buildings and enabling and / or requiring work from home arrangements for those able to do so;
- · Cancellation of events, such as Festival of Trees;
- Enhanced restraints on discretionary spend;
- Participation in the national Frontline Fund fundraising initiative;
- Participation in the provincial Foundations of Gratitude front-line worker appreciation campaign;
- Launch of a local COVID-19 Emergency Response fundraising campaign; and
- Application to the Temporary Wage Subsidy program and the Canada Emergency Wage Subsidy program.

At this time these factors present uncertainly over future cash flows, may cause significant changes to the assets or liabilities and may have a signification impact on future operations. An estimate of the financial effect is not practicable at this time.

Schedule 1 - Fund Balances (continued)

	Opening Balance	(	Current year				
	March 31, 2019	Allocated Investment Income	Donations	Distributions and Transfers	March 31, 2020		
UNIVERSITY OF ALBERTA HOSPITAL - PATIENT CARE, RESEARCH	H & EDUCATION						
<u>Arthritis</u>							
Hugh H. & Annabelle C. Millar Fund for Arthritis Research	674,719	9,205	-	(61,061)	622,863		
Betty B. Drury Fund in support of Rheumatology	658,167	9,873	-	-	668,040		
Dr. Donald Stanley Special Purpose Fund for Clinical Research in Rheumatoid Arthritis	87,214	1,308	-	-	88,522		
Total Arthritis Funds	1,420,100	20,386	-	(61,061)	1,379,425		
Brain Centre							
UHF Brain Centre Campaign Fund	10,352,665	169,090	-	920,035	11,441,790		
Leona & Kenneth Biggs Fund	-	28,267	5,031,404	-	5,059,671		
University Hospital Foundation Board Fund	1,122,364	14,954	-	(125,397)	1,011,921		
Mildred I. Olsen Fund for Neurology Research	1,041,331	13,875	-	(116,344)	938,862		
Dr. Rowland & Muriel Haryett Fund for Innovation in Neurosciences	874,687	13,120	-	-	887,807		
Allan H. Owen & Family Stroke Chair Fund	816,453	11,719	-	(35,158)	793,014		
James & Jeanie Brown ALS Innovation Education & Research Fund	511,970	3,930	-	(250,000)	265,900		
E. (Ben) & Mary Hochhausen Fund for Epilepsy & Cerebral Palsy Research	426,758	6,182	10,204	(18,077)	425,067		
Dennis M. Erker Parkinson's Innovation & Research Fund	261,680	4,168	20,000	-	285,848		
Wismer Fund in support of Myasthenia Gravis	233,535	3,410	6,255	(8,000)	235,200		
Multiple Sclerosis Outreach Wellness Navigator Fund	114,797	130	-	(106,163)	8,764		
Anne Iris Reiser Fund in support of Research & Treatment of Brain Disorders & Diseases	101,862	1,528	-	-	103,390		
George & Eileen Smith Brain Innovation Fund	63,898	1,585	50,000	-	115,483		
Marjorie Lewis Cable Medical Research Memorial Fund	57,352	860	-	=	58,212		
Lyle Hawkins Fund in Support of Alzheimer's Disease Research	53,246	799	-	=	54,045		
United Parkinson's Disease Research & Patient Care Fund	51,771	744	-	(2,199)	50,316		
H.W. Skaret Endowment Fund	44,214	639	1,000	(1,873)	43,980		
Dr. Keith Aronyk Fund	-	170	41,007		41,177		
Evelyn Harkness McKenzie Fund for Parkinson's Disease Research	31,131	447	-	(1,341)	30,237		
Judy Laviolette Memorial Fund in support of Neurology	25,937	389	-	-	26,326		
Aleda Patterson Fund in support of Parkinson's Education	-	98	25,000	- (0.74.0)	25,098		
Carolyn Ann MacDonald Fund	24,254	323	-	(2,710)	21,867		
Reddon-Valens MS Research Fund	19,658	282 272	-	(847)	19,093		
Douglas Arthur Pettitt Memorial Fund in support of Research & Patient Care for Ehlers Danlos Syndrome	18,139	212	-	-	18,411		
Mei Lee Fung Memorial Fund for Treatment, Research & Prevention of Stroke	12,850	184	-	(553)	12,481		
Total Brain Centre Funds	16,260,550	277,165	5,184,870	251,373	21,973,958		

Schedule 1 - Fund Balances (continued)

	Opening Balance		Current year				
	March 31, 2019	Allocated Investment Income	Donations	Distributions and Transfers	March 31, 2020		
UNIVERSITY OF ALBERTA HOSPITAL - PATIENT CARE, RESEARCH	I & EDUCATION (c	ontinued)					
Burn Unit							
Firefighters' Burn Camp Established Fund	619,358	9,290	-	-	628,64		
Harold & Emilie Tucker Memorial Fund	225,743	3,246	672	(9,708)	219,95		
Alfred Drader Fund	153,317	2,201	-	(6,602)	148,91		
Firefighters' Burn Unit Treatment, Patient Care & Education Fund	96,034	2,361	236,266	(150,000)	184,66		
George A. Taylor Memorial Fund	8,711	124	=	(375)	8,46		
otal Burn Unit Funds	1,103,163	17,222	236,938	(166,685)	1,190,63		
<u>'ancer</u>							
Dianne and Irving Kipnes Establishment Grant for Chair in Lymphatic Disorders Fund	2,000,000	93,820	=	=	2,093,8		
Ilard Foundation Cancer Research Fund	1,549,903	23,249	=	=	1,573,1		
tia & Cory Wild Fund for Childhood Cancer Research	402,897	3,939	-	(140,298)	266,5		
lesley C. Stone Fund for Cancer Research	205,866	3,088	-	-	208,9		
da Hoffman Cancer Research Fund	174,556	2,618	-	-	177,1		
rederick T. Jenner Memorial Scholarship Fund for Cancer Research & Education	161,624	-	-	(161,624)			
ileen Nash Memorial Fund created by Kathy & Ross Grieve	142,249	1,384	=	(50,000)	93,6		
Catherine Laschowski Fund for Cancer Research	54,863	=	=	(54,863)			
Mary Talbot Memorial Fund for Cancer Research	45,406	-	-	(45,406)			
r. W.W. Burnett Memorial Fund for Bone Cancer Education & Research	12,389	185	-	-	12,5		
otal Cancer Funds	4,749,752	128,283	-	(452,191)	4,425,84		
<u>Diabetes</u> C.F. "Curly" & Gladys MacLachlan Fund for Islet Molecular Biology & Islet Transplantation	1,337,821	20,067		_	1,357,8		
aboratories in support of Diabetes Mellitus Research	1,001,021	20,007	-	-	1,337,0		
addy & Ken Webb & Family Fund in support of Diabetes Mellitus Research	512,354	7,685	_	_	520.0		
/illiam H. (Pete) & June Johnson Memorial Fund in support of Pediatric Diabetes Research	•	1.135	6,920	(1,000)	79,7		
Care	12,000	1,100	0,020	(1,000)	73,7		
Bud & Joyce Byram Fund for Diabetes Research	7,201 -	108		<u>-</u>	7,3		
otal Diabetes Funds	1,930,069	28,995	6,920	(1,000)	1,964,9		

Schedule 1 - Fund Balances (continued)

	Opening Balance	(	Closing Balance		
	March 31, 2019	Allocated Investment Income	Donations	Distributions and Transfers	March 31, 2020
UNIVERSITY OF ALBERTA HOSPITAL - PATIENT CARE, RESEARCH	I & EDUCATION (c	ontinued)			
<u>Equipment</u>					
Anonymous Fund in support of High Priority Equipment Needs	637,412	7,776	61,789	(150,000)	556,977
Fred & Mil Vincett Fund in support of Patient Care Equipment	163,563	2,453	-	-	166,016
J. Gordon & Millicent C. McDonald Memorial Fund in support of High Priority Patient Care	40,311	605	-	-	40,916
Equipment					
Frances R. Bundle Memorial Fund	15,928	239	-	-	16,167
Albert Michael & Phyllis Mary Mort Fund in support of High Priority Equipment	3,621	54	-	-	3,675
Total Equipment Funds	860,835	11,127	61,789	(150,000)	783,751
<u>Gastroenterology</u>					
LeRoy & Karen Sonnenberg Fund to support Fecal Microbiota Transplantation	361,815	5,793	100,000	-	467,608
Robert & Shirley Stollery Fund for Inflammatory Bowel Disease Education & Research	76,303	1,145	-	=	77,448
Jack & Zita Rosen Fund in support of Gastroenterology	31,527	473	-	-	32,000
William F. Lede Fund for the Gastroenterology Fellowship Program	25,339	380	-	=	25,719
Paul Bowlen Liver – Dr. R.H. Wensel Trust Fund for a Visiting Professorship in Hepatology	10,792	162	-	-	10,954
John Berezon – Dr. R.H. Wensel Trust Fund for Gastroenterology Education	7,614	114	-	-	7,728
Total Gastroenterology Funds	513,390	8,067	100,000	-	621,45
<u>Genetics</u>					
University Hospital Foundation Fund for Medical Genetics	836,000	12,000	-	(36,000)	812,000
Gilbert K. Winters Fund in support of Severe Infant Skeletal Deformity	533,473	7,658	<u>-</u>	(22,973)	518,158
Total Genetics Funds	1,369,473	19,658	-	(58,973)	1,330,158

Schedule 1 - Fund Balances (continued)

	Opening Balance	(	Current year	<u> </u>	Closing Balance
	March 31, 2019	Allocated Investment Income	Donations	Distributions and Transfers	March 31, 2020
UNIVERSITY OF ALBERTA HOSPITAL - PATIENT CARE, RESEARC	:H & EDUCATION (c	ontinued)			
Medical Research Competition					
Eric & Helena Douglass Fund in support of Clinical Research	2,379,475	34,233	_	(97,257)	2,316,45
Stanley E. Robins Special Purposes Medical Research Fund	1,813,693	26,238	-	(64,487)	1,775,44
Muriel Robins Fund for Clinical Research	821,484	12,039	-	(18,866)	814,65
Gary Rees Garson Medical Research Fund	500,379	7,185	370	(21,539)	486,39
University Hospital Foundation Board Fund	255,312	3,665	-	(10,994)	247,98
Ruth Robertson Memorial Fund in support of Heart & Cancer Research	235,198	3,528	-	-	238,72
Oon & Mary Cunningham Fund for Clinical Research	211,874	3,041	-	(9,124)	205,79
King H. Mok Fund in support of Medical Research	191,365	2,748	-	(8,135)	185,97
George & Margaret McNeill Fund	172,475	2,548	9,338	(7,256)	177,10
Marcia & Dorothy May Hallett Special Purpose Fund	166,253	2,386	-	(7,159)	161,48
illian Doris Nielsen Fund in support of Diabetes, Pediatric Research, Cardiac & Stroke	123,879	1,778	-	(5,335)	120,32
Projects or Programs					
Villiam & Betty Rathje Fund for Heart & Cancer Research	103,934	1,559	-	-	105,49
Intonio & Angelina Biamonte Clinical Research Memorial Fund	98,099	1,408	-	(4,224)	95,28
Sophie Buttner Fund in support of Medical Research	53,392	766	-	(2,299)	51,8
atrina Witwicky Memorial Fund for Clinical Research	52,137	748	-	(2,245)	50,64
sabella Tulloch Memorial Fund	50,965	732	-	(2,195)	49,50
rene Samuel Fund	46,568	668	-	(2,005)	45,23
Ross & Gwen Harris Fund for Clinical Research	44,245	636	-	(1,857)	43,02
ohn Antku Fund	14,570	209	-	(627)	14,1
gnes Y. Fleming Special Purpose Fund to Enrich Medical Research	10,913	157	-	(470)	10,60
Villiam H. Roxburgh Memorial Fund	5,820	84	-	(251)	5,6
lary Allardyce Cross Endowment Fund	3,820	55	-	(164)	3,7
Diga Pond Fund	322	6	-	(14)	3
Total Medical Research Competition Funds	7,356,172	106,417	9,708	(266,503)	7,205,79

Schedule 1 - Fund Balances (continued)

	Opening Balance	(	Current year			
	M	Allocated Investment	<b>.</b>	Distributions	M	
	March 31, 2019	Income	Donations	and Transfers	March 31, 2020	
UNIVERSITY OF ALBERTA HOSPITAL - PATIENT CARE, RESEARCH	& EDUCATION (c	ontinued)				
Medicine						
Marshall Eliuk Fund for Exemplary Care in Hematology	1,820,745	22,956	-	(290,366)	1,553,33	
Muhlenfeld Family Trust Fund	992,750	14,291	-	(40,000)	967,04°	
Canadian Biomaterials Society	44,338	665	-	=	45,003	
Mary M. Bekker Fund in support of Adult Orthopedic Nursing	34,290	514	-	-	34,80	
Charles McDougall & Sandra Versteeg-McDougall Fund for Senior Urology Resident Award	29,060	406	-	(2,000)	27,46	
Patricia D. Yates & Arthur D.G. Yates Fund in support of Adult Orthopedic Medicine	20,887	314	-	-	21,20	
Total Medicine Funds	2,942,070	39,146	=	(332,366)	2,648,850	
Mental Health						
Psychiatry Research Fund	726,480	10,897	-	-	737,37	
Anonymous Fund for Study, Research & Treatment of Mental Illness	548,684	8,230	-	-	556,91	
Simon & Martina Sochatsky Fund for Mental Health Research & Patient Care	93,940	1,455	10,999	-	106,39	
Howard Berger Memorial Schizophrenia Research Fund	57,796	867	-	=	58,66	
Abraham & Freda Berger Memorial Fund in support of Psychiatric Research	30,828	462	-	-	31,29	
Dr. Masuru Yukawa Award for Innovation in Workplace Wellness	-	24	25,475	-	25,49	
Total Mental Health Funds	1,457,728	21,935	36,474	-	1,516,13	
Nephrology						
Matt & Betty-Jean Baldwin Home Hemo Fund in support of the Home Hemodialysis	1,141,985	19,061	250,000	-	1,411,04	
Program						
Allan Wallace Peterson Fund for Kidney related Research & Equipment	40,095	601	-	-	40,69	
Ronald & Arda Baltzan Fund for Kidney Research	16,093	242	-	-	16,33	
Total Nephrology Funds	1,198,173	19,904	250,000	-	1,468,07	

Schedule 1 - Fund Balances (continued)

	Opening Balance	(	Current year			
	March 31, 2019	Allocated Investment Income	Donations	Distributions and Transfers	March 31, 2020	
	,		Donations	and transfers	Warch 31, 2020	
JNIVERSITY OF ALBERTA HOSPITAL - PATIENT CARE, RESEARCH	ł & EDUCATION (c	ontinued)				
Jursing Education						
Ruth A. (Poole) Van Dusen Memorial Fund for Nursing Scholarships funded by John E. & Barbara Poole Family	433,254	6,274	-	(15,000)	424,52	
ames Yi & Wei Chiwei Fund for Nursing Scholarships	284,735	4,121	=	(10,000)	278,8	
ernice Sharon Magee Professional Development Fund in support of Nursing	-	1,769	206,180	-	207,94	
lisabeth Palate Nursing Education Fund	186,532	2,705	3,000	(7,000)	185,2	
niversity Hospital Foundation Nursing Scholarships Fund	59,226	851	-	(2,500)	57,5	
ernice Sharon Magee Scholarship in Nursing	-	443	51,080		51,5	
renda Moffitt Memorial Fund in support of Nursing Education	43,540	653	-	-	44,1	
ichael J. Lahey Nursing Scholarship Fund	30,315	435	-	(1,300)	29,4	
r. Robert M. Shaw Memorial Fund	28,375	411	-	(1,000)	27,7	
udy (Patmore) Klaczek Memorial Fund in support of Nursing Education	26,961	390	30	(1,000)	26,3	
otal Nursing Education Funds	1,092,937	18,052	260,290	(37,800)	1,333,4	
<u>phthalmology</u>						
live Young Special Purpose Fund for Ophthalmology Research	329,547	4,730	-	(14,191)	320,0	
he Catherine McLean Fund in support of Ophthalmology	206,975	3,105	-	=	210,0	
otal Ophthalmology Funds	536,522	7,835	-	(14,191)	530,1	
atient Compassionate Support						
ilbur & Marjorie Bowker Compassionate Support Services Fund	328,611	4,929	-	-	333,	
ultgen-Lees Memorial Fund for Maintenance & Care of Patients with Acquired Immune	201,627	3,024	-	-	204,6	
ficiency Syndrome						
onymous Foundation Compassionate Support Fund	143,976	2,160	-	-	146,	
nonymous Compassionate Support Fund	71,988	1,080	-	-	73,	
otal Patient Compassionate Support Funds	746,203	11,193	=	-	757,	

Schedule 1 - Fund Balances (continued)

	Opening Balance		Current year	_	Closing Balanc
	March 31, 2019	Allocated Investment Income	Donations	Distributions and Transfers	March 31, 2020
UNIVERSITY OF ALBERTA HOSPITAL - PATIENT CARE, RESEARC	H & EDUCATION (	continued)			
Pediatrics					
Stjepan Posavec Fund to benefit Children with Physical Handicaps	107,951	1,507	=	(7,500)	101,9
Michaell Shirvell Griffin Memorial Fund	78,125	1,063	5,000	(8,507)	75,6
Total Pediatrics Funds	186,076	2,570	5,000	(16,007)	177,6
Pulmonary					
Agnes D. Lynch Fund for the Respiratory Outreach Centre	507,379	7,611	-	-	514,9
Pulmonary Division Research & Academic Fund to support all Academic Activities within the Division of Pulmonary Medicine	101,749	1,526	-	-	103,2
Egerton W. King Fund for Childhood Asthma Research	98,351	1,474	=	=	99,8
Dr. Brian Sproule Fund for Education & Research in Pulmonary Medicine	58,944	884	=	=	59,8
Dr. D. Young Memorial Fund for Visiting Speakers of the Lung Transplantation Program	32,237	484	-	-	32,7
Thyra Parker Special Purpose Fund for Cystic Fibrosis Research	18,179	273	-	-	18,4
Total Pulmonary Funds	816,838	12,252	-	-	829,0
<u>Surgery</u>					
James Yi & Wei Chiwei Fund in support of the General Surgery Residents' Retreat	197,917	2,969	-	-	200,8
		-	-	=	
<u>Transplantation</u>		-	-	-	
S. Jean Milner Fund for Continuing Education & Research in Thoracic Organ  Fransplantation	580,827	8,712	-	-	589,5
The Lung Transplant Rehabilitation Education & Research Fund	320,782	5,115	36,870	-	362,7
Klaus & Helga Rieder Fund for Kidney Transplant Research & Education	111,664	1,675	-	-	113,3
Dr. Harald & Dr. Berta Kuckertz in Support of Organ Transplant Research	60,788	912	-	-	61,7
Total Organ Transplantation	1,074,061	16,414	36,870	-	1,127,3
TOTAL UNIVERSITY OF ALBERTA HOSPITAL	\$ 45.812.029	\$ 769.590 \$	6.188.859	\$ (1,305,404)	\$ 51,465,

Schedule 1 - Fund Balances (continued)

	Opening Balance	(	Current year			
	March 31, 2019	Allocated Investment Income	Donations	Distributions and Transfers	March 31, 2020	
MAZANKOWSKI ALBERTA HEART INSTITUTE - PATIENT CARE, RESEARCH & EDUCA	ATION					
Cardiac Sciences						
MacDonald Cardiac Sciences Talent & Technology Fund	11,201,570	165,642	200	(158,880)	11,208,532	
Stuart & Winona Davis Fund in support of Mazankowski Alberta Heart Institute	7,089,641	106,345	-	-	7,195,986	
Dr. Arvind Koshal Advancement Fund	3,226,720	42,412	2,500	(400,000)	2,871,632	
Jose Luis & Dina Arrese Goicoa Fund in support of the Mazankowski Alberta Heart Institute	2,029,579	30,444	=	- 1	2,060,023	
Gerald Averback Medical Research Fund	1,990,071	29,851	-	-	2,019,92	
Robert Marko Memorial Fund in support of the Mazankowski Alberta Heart Institute	1,439,763	21,596	-	-	1,461,359	
Villiam H. (Bill) Caine & Terry M. Caine Fund	888,391	13,326	-	-	901,71	
Pr. Rowland & Muriel Haryett Fund for Cardiac Surgery Clinical Innovation	615,468	9,232	-	-	624,70	
Richard E. Rossall Arrhythmia & Valvular Heart Disease Academic Trust Fund	553,606	8,045	10,000	(20,000)	551,65	
yle & Kathryn Abraham Fund in support of the Mazankowski Heart Institute	282,914	3,986	20,000	(22,914)	283,98	
Pearl & Armand Nielsen Fund in support of Cardiac Surgery	240,023	3,809	75,000	(23,725)	295,10	
awrence & Shirley Henderson Fund in support of Cardiology	230,562	3,546	40,000	(7,996)	266,11	
Greg & Aurdrey Greenough Cardiac Sciences Fund in Memory of Dr. Norman Davies	191,647	2,875	-	-	194,52	
r. Neil Duncan/Children's Heart Society Fund for Pediatric Cardiology	145,571	2,183	-	-	147,75	
tick Cormier Memorial Fund in support of the Mazankoski Alberta Heart Institute	83,047	1,252	1,200	-	85,49	
yan Tiltgen Memorial Fund for Pediatric Cardiology	79,070	1,186	-	-	80,25	
ay & Joan Joberty Fund in support of the Mazankowski Alberta Heart Institute	44,078	677	2,000	-	46,75	
lartin & Carlene Stoklossa Fund for Cardiac Patient & Family Care	41,382	621	=	-	42,00	
lary & George Shreeves Fund for the Advancement of Cardiac Sciences	38,473	581	1,000	-	40,05	
on Skuba Arrhythmia Research Fund	30,797	467	600	-	31,86	
ediatric Cardiology Training Fund	20,055	301	=	-	20,35	
Matilda (Kelly) Poirier Fund in support of Research in the Heart Transplant Program	8,013	107		(895)	7,22	
otal Cardiac Sciences Funds	30,470,440	448,484	152,500	(634,410)	30,437,0	

Schedule 1 - Fund Balances (continued)

	Opening Balance		Current year			
	March 31, 2019	Allocated Investment Income	Donations	Distributions and Transfers	March 31, 2020	
MAZANKOWSKI ALBERTA HEART INSTITUTE - PATIENT CARE, RESEARCH & EDU	CATION (continued)					
Cardiac Sciences - Research						
Heart Function Clinic	1,000,000	15,000	-	-	1,015,000	
Dr. Joseph Dvorkin Memorial Fund for Cardiology Education & Research	198,105	2,972	-	-	201,077	
Nick & Margret Oneschuk Fund in support of Cardiac Research	109,805	1,647	-	-	111,452	
Olga Pollock Fund in support of Heart & Stroke Research	102,443	1,536	-	=	103,979	
Total Cardiac Sciences - Research	1,410,353	21,155	-	-	1,431,508	
Cardiovascular & Thoracic Surgery (John Carter Callaghan Chair)						
University Hospital Foundation Board Fund	542.867	7,233	-	(60,652)	489,448	
Anonymous Fund	471,096	6,277	-	(52,634)	424,739	
George E. Mucha Fund	127,798	1,720	2,500	(13,878)	118,140	
John G. Mucha Family Trust	108,070	1,457	2,500	(11,684)	100,343	
Robert & Shirley Stollery Fund	101,782	1,356	, <u>-</u>	(11,372)	91,766	
Benny & Olga Elkow Fund	53,775	769	3,425	(5,788)	52,181	
Nelson Lumber Foundation Fund	53,759	716	-	(6,006)	48,469	
Greg & Audrey Greenough Fund	47,948	639	-	(5,357)	43,230	
rene Dyck Memorial Fund	31,267	417	-	(3,493)	28,191	
Joe Check Fund	28,356	378	-	(3,168)	25,566	
Lawrence & Luiba Trahan Fund	20,089	268	-	(2,218)	18,139	
Alvin & Mona Libin Fund	18,843	251	-	(2,105)	16,989	
Ray & Joan Joberty Fund	12,019	160	-	(1,343)	10,836	
Helene Girard Fund	9,532	127	-	(1,065)	8,594	
Mildred I. Olsen Fund	9,020	120	-	(1,008)	8,132	
Reuben & Goldie Cipin Fund	6,854	91	-	(766)	6,179	
Joe & Dolores Bruchal Special Purpose Fund for Cardiovascular Surgery Education and Research	2,157	30	-	(242)	1,945	
Total Cardiovascular & Thoracic Surgery	1,645,233	22,009	8,425	(182,779)	1,492,888	
TOTAL MAZANKOWSKI ALBERTA HEART INSTITUTE	\$ 33,526,026	\$ 491,648 \$	160,925	\$ (817,189)	\$ 33,361,410	

Schedule 1 - Fund Balances (continued)

	Opening Balance		Current year			
	March 31, 2019	Allocated Investment Income	Donations	Distributions and Transfers	March 31, 2020	
KAYE EDMONTON CLINIC - PATIENT CARE, RESEARCH & EDUCATION						
Family Medicine						
Dr. Scott McLeod Family Medicine Memorial Fund funded by John & Barbara Poole Family	1,016,759	13,547	-	(113,598)	916,708	
Kaye Edmonton Clinic	45.004.504	242.000		(4.400.050)	44.400.400	
The Kaye Fund Prostate and Urology Health Innovation and Research Fund	15,304,564 4,688,247	212,928 70,524	25,000	(1,109,353)	14,408,139 4,783,771	
Dianne & Irving Kipnes Urology Centre Innovation & Research Fund	1,018,615	13,913	1,000,600	(504,961)	1,528,167	
Dr. J. B. Metcalfe Urology Physicians Fund	-	1,456	181,385	-	182,841	
Prostate Innovation Fund Total Kaye Edmonton Clinic	21,011,426	- 298,821	1,206,985	(1,614,314)	20,902,918	
Total Raye Edmonton Clinic	21,011,420	290,021	1,200,965	(1,614,314)	20,902,916	
TOTAL KAYE EDMONTON CLINIC	\$ 22,028,185	\$ 312,368 \$	1,206,985	\$ (1,727,912)	\$ 21,819,626	
HIGHEST PRIORITY / GENERAL PURPOSE						
Festival of Trees Fund	1,166,652	15,324	-	(145,075)	1,036,901	
R. John & Agnes M. Adams Fund	260,425	2,738	-	(77,925)	185,238	
Al & Wendy Bryan Fund for the Annual Campaign	226,815	3,432	2,566	-	232,813	
John Romanchuk Fund	190,091	1,991	-	(57,341)	134,741	
Capital Packers Inc./Komarnicki Family Fund	170,420	2,045	5,000	(35,420)	142,045	
B. Martha Moritz Fund	155,202	1,538	=	(52,702)	104,038	
Roger & Peggy Gouin Fund Albert Drews Fund	151,706	1,650	-	(41,706)	111,650	
William Kenneth Drake Fund	143,882	1,463	-	(46,358)	98,987	
Reinhard Henschel Fund	138,606 137,493	1,500 1,500	-	(38,606) (37,493)	101,500 101,500	
Frances Olson Special Purpose Fund for the Annual Campaign	131,576	1,974	_	(37,493)	133,550	
Richard & Trudy Cormier Fund	121,491	1,323	-	(33,324)	89,490	
Ada & Fred Carpenter Fund	117,220	1,758	-	(55,524)	118,978	
Donald & Betty Carlson Fund	110,147	1,504	_	(9,897)	101,754	
Garry & Joyce Rathgeber Fund	107,150	1,236	5,000	(26,467)	86,919	
Leo S. & Doris E. Hester Memorial Fund	97,751	1,017	-	(29,936)	68,832	
Winnifred Henning Fund	93,406	1,001	-	(26,656)	67,751	
Helen Nemirsky Memorial Fund	90,514	1,037	3,500	(22,514)	72,537	

Schedule 1 - Fund Balances (continued)

	Opening Balance	(	Current year		Closing Balance
	March 31, 2019	Allocated Investment Income	Donations	Distributions and Transfers	March 31, 2020
HIGHEST PRIORITY / GENERAL PURPOSE (continued)					
Bill & Betty Sinclair Fund	83,725	856	-	(26,658)	57,923
Cecille Shtabsky Special Purpose Fund for the Annual Campaign	80,426	1,206	=	-	81,632
Beuerlein Estate & Maguire Trust for the Annual Campaign	78,891	1,183	=	-	80,074
Walter Louis Batke Fund	70,730	757	-	(20,246)	51,241
Anonymous Fund	43,644	450	-	(13,644)	30,450
Elizabeth & Clarence Preitz Fund	37,663	426	-	(9,251)	28,838
Isidor & Grace Gliener Fund	35,562	384	=	(9,962)	25,984
John & Mary Sterenberg Fund	35,270	428	2,457	(8,099)	30,056
Alex Romaniuk Memorial Fund	35,228	389	-	(9,326)	26,291
Machum Family Fund	34,868	423	2,000	(8,613)	28,678
Thomas Rhatigan Fund for the Annual Campaign	34,682	520	=	-	35,202
Leonard Vernon Kallis General Purpose Fund	34,652	375	-	(9,652)	25,375
T.S. & Mary Wilson Fund	31,403	238	-	(15,535)	16,106
Florence Thomas Fund for the Annual Campaign	28,534	428	=	-	28,962
Shenaz & Azim Jeraj Special Purpose Fund	24,593	277	-	(6,110)	18,760
Janelle Newton Fund	17,162	188	-	(4,662)	12,688
Bryan & Kathy O'Donnell Fund	16,412	87	=	(10,580)	5,919
Jack & Audrey Holmes Fund	15,989	173	=	(4,489)	11,673
Bernard Marvin Sheehan Memorial Fund	15,148	75	-	(10,148)	5,075
Donald R. & Elizabeth B. Brandt Fund	13,995	151	=	(3,897)	10,249
Jessie W. Templeman Fund	13,992	150	=	(3,992)	10,150
Gordon Cameron Fund	11,120	114	-	(3,489)	7,745
Rick & Nikki Vogel Special Purpose Fund	9,444	142	=	-	9,586
Gail & Harold Taylor Fund	7,200	78	-	(1,975)	5,303
Maria Adrienne Orn Fund	6,950	75	-	(1,950)	5,075
To Ha & Hung Diep Dang Fund in support of High Priority Equipment	3,201	71	3,500	-	6,772
Total Highest Priority / General Purpose Funds	4,431,030	53,675	24,023	(863,698)	3,645,030

Schedule 1 - Fund Balances (continued)

	Opening Balance	(	Current year	_	Clo	sing Balance
	March 31, 2019	Allocated Investment Income	Donations	Distributions and Transfers	Ma	arch 31, 2020
SPECIAL PURPOSE						
Dow Hicks Fund in support of Transplant Programs & Medical Research	1,987,680	29,815	-	-		2,017,495
Chint Kaur Lali & Boota Singh Lali Endowment Fund	309,033	4,650	1,000	-		314,683
Dr. R.E. Bell Memorial Fund for a Visiting Professor	182,492	2,786	10,205	=		195,483
Dorothy & Walter Mackenzie Memorial Fund	179,875	2,719	5,000	=		187,594
Dr. Claude V. Jamieson & Dr. Heber C. Jamieson Memorial Fund in support of the Nuclear Magnetic Resonance Research Centre	76,827	1,024	-	(8,584)		69,267
Jacoba Vanthof Fund in support of Diabetes & Cardiac Research	61,524	923	-	-		62,447
Dr. Robert James Kelly Global Health Memorial Fund	60,852	941	3,000	=		64,793
Tevie & Arliss Miller Fund in support of the Bioethics Centre	37,224	527	1,000	(2,556)		36,195
Dr. Lorne Tyrrell Board Restricted Fund to support the Tyrrell Lectureship in Medical	24,161	362	-	-		24,523
Microbiology & Immunology						
Adarsh Gopal Education & Research Fund	15,626	272	5,000	=		20,898
Total Special Purpose Funds	2,935,294	44,019	25,205	(11,140)		2,993,378
TOTAL ESTABLISHED FUNDS	\$ 108,732,564	\$ 1,671,300 \$	7,605,997	\$ (4,725,343)	\$	113,284,518
		Non-Establishe	ed Internally Re	estricted Funds		4,781,963
		Non-Established	d Externally Re	estricted Funds		31,407,793
			•	estricted Funds		15,241,702
		Non-Es	stablished End	owment Funds		-
			Invested i	n capital assets		40,370
				Total net assets		164,756,346

Schedule 2 – Investment Income

	End	dowment Funds	Externally Restricted Funds	Internally Restricted Funds	Unrestricted Funds	Total 2020	Total 2019
Interest Dividends Realized gains	\$	3,306 - -	\$ 1,563,762	\$ 230,128	\$ 3,270,050 524,071 7,559,289	\$ 5,067,246 524,071 7,559,289	\$ 5,060,625 469,856 2,355,003
Realized investment income		3,306	1,563,762	230,128	11,353,410	13,150,606	7,885,484
Unrealized gain (loss)		-	-	-	(13,662,406)	(13,662,406)	1,546,851
Total	\$	3,306	\$ 1,563,762	\$ 230,128	\$ (2,308,996)	\$ (511,800)	\$ 9,432,335